U.S., Dec. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07260591) titled 'VSV-02 Compassionate Use in Advanced Solid Tumors' on Sept. 26.
Brief Summary: This is a clinical study for patients with advanced solid tumors who have limited or no effective treatment options available. The study aims to evaluate a new investigational drug called VSV-02 Injection, which is developed by Shanghai Rongrui Pharmaceutical Technology Co., Ltd.
The main purpose of this open-label, single-arm study is to assess the preliminary effectiveness and safety of VSV-02 when it is given through two routes: directly into a vein (intravenously) and by injection directly into the tumor (intratumorally). Patients will receive the tre...